GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evogene Ltd (XTAE:EVGN) » Definitions » Capex-to-Operating-Income

Evogene (XTAE:EVGN) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Evogene Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Evogene's Capital Expenditure for the three months ended in Dec. 2023 was ₪-0.32 Mil. Its Operating Income for the three months ended in Dec. 2023 was ₪-28.48 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Evogene Capex-to-Operating-Income Historical Data

The historical data trend for Evogene's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evogene Capex-to-Operating-Income Chart

Evogene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Evogene Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Evogene's Capex-to-Operating-Income

For the Biotechnology subindustry, Evogene's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evogene's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evogene's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Evogene's Capex-to-Operating-Income falls into.



Evogene Capex-to-Operating-Income Calculation

Evogene's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-2.931) / -98.986
=N/A

Evogene's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.321) / -28.484
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evogene  (XTAE:EVGN) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Evogene Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Evogene's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Evogene (XTAE:EVGN) Business Description

Industry
Traded in Other Exchanges
Address
13 Gad Feinstein Street, Park Rehovot, P.O. Box 4173, Ness Ziona, Rehovot, ISR, 7414002
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment.